A prospective, multicenter, randomized, open‐label, 2-parallel group, Phase 2 study to evaluate the efficacy and the safety of masitinib at 9 mg/kg/day in combination with docetaxel or with gemcitabine in metastatic Hormone Refractory Prostate Cancer (HRPC) in progression after first line of treatment.

Trial Profile

A prospective, multicenter, randomized, open‐label, 2-parallel group, Phase 2 study to evaluate the efficacy and the safety of masitinib at 9 mg/kg/day in combination with docetaxel or with gemcitabine in metastatic Hormone Refractory Prostate Cancer (HRPC) in progression after first line of treatment.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Masitinib (Primary) ; Docetaxel; Gemcitabine; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 Status changed from active, no longer recruiting to completed, according to an AB Science media release.
    • 20 Feb 2014 Preliminary results from the masitinib + docetaxel + prednisone arm have been reported in an AB Science media release.
    • 05 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top